Search This Blog

Sunday, November 22, 2026

Are GLP-1s Enabling Disordered Eating?

 I often open my obesity medicine visits by asking "How are you feeling today?" Today the answer was, "I feel like the medication is finally working!"

I checked the chart to find that the patient was down 21 pounds in 3 months, or about 6% of bodyweight. When I dug in and asked about dietary intake, she reported that after switching to tirzepatide (Mounjaro, Zepbound) 2 weeks ago, she spontaneously decided the best way to take control of her life was to start a water fast. She was currently on day 13 of only water and diet coke and stated she felt "amazing." I reviewed her vitals and her heart rate was 127. After a few questions, she admitted she wasn't sleeping due to stress and then burst into tears. She told me she wanted to go up on both her GLP-1 and her oral weight loss medications so she could continue water fasting indefinitely.

Based on my level of clinical concern, I discontinued her weight control medications, referred her to the local eating disorders center, scheduled her a visit with the dietitian, and scheduled a close follow-up to ensure she was receiving these additional forms of care.

On another occasion, my phone rang. It was an emergency doctor who I've known for years: "Hey, I need to curbside on a patient."

The doctor told me that a patient was brought into the emergency department after fainting and hitting her head. She reported feeling fine but not drinking as much water as usual. The patient's husband reported that she had been receiving a GLP-1 receptor agonist from the local med spa and "was working out 2 hours a day and only eating an apple and a protein shake a day" while at a body mass index of 21. Lab work revealed the patient was deficient in numerous electrolytes, including potassium, magnesium, and phosphorous. After receiving fluids, he reported that "the patient left and stated she had no plans to stop the medication."

Obesity is a chronic disease that affects over a billion people globally. For five decades, there were no highly effective medication options for treatment, with safe options providing only limited benefits. Over the past 6 years, that has radically changed: multiple long-acting medications for chronic weight management have been approved by FDA and widely adopted. GLP-1s have more than doubled medical treatment efficacy compared to prior medication options. Semaglutide (Ozempic, Wegovy) and tirzepatide reduce spontaneous food intake by hundreds of calories a day, on average, and can produce weight loss of up to 30% of bodyweight in some individuals.

However, with this substantial breakthrough comes the risk of over-suppression of appetite. The speed of weight loss is akin to driving a fast car down a highway: it's done best with limits and attention to safety concerns.

The wide variability in individual responsiveness to GLP-1s produces a challenging clinical scenario for chronic obesity treatment in some patients. While a minority do not lose weight on GLP-1 medications, others may experience profound reductions in hunger and food-related cognitions (also known as "food noise"). On the extreme end, I have witnessed some patients spontaneously lose nearly half their bodyweight. This variability is reflected by field-leading clinical trials. With a drug this powerful, every individual must be monitored and medications tailored to their needs.

Based on the experiences of patients described earlier, I strongly counsel my patients on health and nutritional intake to avoid malnutrition, especially for patients suffering gastrointestinal side effects, including nausea, vomiting, or diarrhea. Because GLP-1s can limit the thirst reflex as well, raising the risk of dehydration and acute kidney injury, it is imperative that patients understand proper hydration.

Meanwhile, a recent meta-analysis showed that approximately one third of patients seeking medical obesity treatment report binge eating behaviors. The lifetime prevalence of eating disorders in the U.S. ranges from 0.6-2% for anorexia nervosa, 1-4.6% for bulimia nervosa, and 0.6-4.5% for binge eating disorder, with younger adults with obesity at significantly higher risk and females at higher risk than males. The evidence that GLP-1 medications will curb hunger does not guarantee these behaviors will be modified, and their presence requires especially careful guidance, understanding, and clinical support.

So, what are clinicians to do? A joint publication by leading medical societies detailed recommendations for nutritional support of patients on GLP-1s, including the need to ensure adequate hydration, protein, fiber, and micronutrient intake. In addition, a 2024 Obesity Reviews publication I co-authored specifically discussed managing these complications.

In my practice, I no longer tell patients to aggressively reduce calorie intake. When I prescribe GLP-1s, I instead instruct them to drink at least 60 oz of water a day, get at least 60 grams of protein a day, and focus on vegetables and solid foods. I also recommend patients consume at least 1,000 calories a day. In our clinic we are fortunate to have dietitians who work with patients on medical therapy to personalize an approachable eating pattern.

Additionally, we ask about history of eating disorders or other psychiatric comorbidities that may indicate risk of disordered eating, while encouraging patients to avoid fasting or excessively restrictive eating schedules. Instead, we focus on patients eating two to three healthy meals a day with adequate nutrition.

For patients who reported current restrictive eating, medications are closely monitored and may be decreased or stopped if those symptoms are worsening or leading to excessive weight loss. For patients with emotional eating as a coping mechanism, we regularly refer to psychology for cognitive behavior therapy and other supportive modalities to help coping behaviors.

More than 100 million patients in America qualify for medical weight loss therapy. At the same time, the rates of eating disorders have risen in the past decades, and these conditions continue to be significantly underdiagnosed. There is a need for a systematic approach to weight loss using GLP-1s, but a "first do no harm" mindset is key. With the impending FDA approval of next generation GLP-1 medications that are significantly stronger, preventing and addressing drug-induced disordered eating will only continue to grow in importance.

Jesse Richards, DO, is an internist and obesity medicine specialist at the University of Oklahoma.

https://www.medpagetoday.com/opinion/second-opinions/123986

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.